AstraZeneca to Acquire Gracell in $1.2 Billion Deal to Further Cell Therapy Goals
…
126,300€
1,41%
Echtzeit-Aktienkurs AstraZeneca PLC
Bid:
Ask:
Nachrichten zur AstraZeneca PLC Aktie
AstraZeneca to buy Gracell Biotechnologies for $1.2 billion
…
AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion
…
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases…
Global Injection Pen Market Analysis and Forecast to 2028, Featuring Analysis of Key Players Sanofi, Eli Lilly, Novo Nordisk, Becton Dickinson, AstraZeneca, F. Hoffmann-La Roche & Merck
Dublin, Dec. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Injection Pen Market: Analysis By Type, By Therapy, By…
Wainua (eplontersen) granted first US FDA approval
22 December 2023
Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated…
Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment
Ionis Pharmaceuticals and AstraZenecas Wainua has been approved by the U.S. Food and Drug Administration for treating a symptom of…
Pharma Stock Roundup: FDA Nod to AZNs Eplontersen, CRL to MRKs Cough Candidate
FDA approves AstraZeneca (AZN) and Ionis (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Mercks chronic cough candidate, gefapixant.…
Ionis (IONS), AstraZenecas Eplontersen Receives FDA Nod
FDA approves Ionis (IONS) and partner AstraZenecas (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.…
Global Biologics Drug Discovery Market Analysis, 2023-2033: Dominated by AbbVie, Amgen, AstraZeneca, and Pfizer
Dublin, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The "Biologics Drug Discovery Market - A Global and Regional Analysis,…
Lloyds, AstraZeneca, BATs, Rolls-Royce: Whats on the menu for 2024?
For investors, the focus in 2024 will be on navigating a year expected to be split into distinct halves. That,…
Assemblin performs extensive multidisciplinary project for AstraZeneca
Assemblin has been commissioned to perform and coordinate multidisciplinary technical installations in the areas of electricity, ventilation, cooling and heating…
Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More
Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.…
Breast Cancer Drugs Global Market Report 2024, Featuring Profiles of Key Players Novartis, AstraZeneca, Eli Lilly, Biocon, Merck and MacroGenics
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Breast Cancer Drugs Global Market Report 2024" has been added…
Atlas Copco Group appoints new Media Relations Manager
Nacka, Sweden, December 14, 2023: Atlas Copco Group has appointed Christina Malmberg Hägerstrand as its new Media Relations Manager.
Christina Malmberg…
The Zacks Analyst Blog Highlights Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources
Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources are part of the Zacks top Analyst Blog.…
AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition
…
AstraZeneca verkündet Milliardenübernahme - Hannover Rück erhöht Ziele
Der Pharmakonzern AstraZeneca erweitert Produktportfolio durch den Zukauf von Icosavax für einen Milliardenbetrag. Hannover Rück hebt die Wachstumsziele für die…
NASDAQ-Titel Icosavax-Aktie +48 %: AstraZeneca kauft Icosavax für Milliardenbetrag - AstraZeneca-Aktie gewinnt
Für bis zu 1,1 Milliarden US-Dollar übernimmt AstraZeneca das US-Biopharma-Unternehmen Icosavax. Damit will Astrazeneca seine Impfstoff- und Immuntherapien-Pipeline ...…
Gastroesophageal Reflux Disease Market to Grow at a Substantial Growth Rate by 2032 - DelveInsight | Key Companies in the Market - Phathom Pharmaceuticals, Microbiome Health Sciences, Takeda, Braintree Laboratories, AstraZeneca
The gastroesophageal reflux disease market is expected to show positive growth, mainly attributed to increased prevalence and the expected launch…
AstraZeneca Buy
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Astrazeneca mit einem Kursziel von 13000 Pence auf "Buy" belassen. Mit…
Icosavax surges 45% in pre-market trading as AstraZeneca agrees takeover
Vaccines specialist Icosavax Inc (NASDAQ: ICVX) is set to surge 45% on Tuesday after agreeing to be taken over by Anglo-Swedish…
UBS belässt Astrazeneca auf Buy - Ziel 13000 Pence
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Astrazeneca mit einem Kursziel von 13000 Pence auf "Buy" belassen. Mit…
AstraZeneca to acquire vaccine maker Icosavax in ~$1.1B deal (NASDAQ:AZN)
In a bid to strengthen its respiratory syncytial virus (RSV) vaccine portfolio, AstraZeneca (NASDAQ:AZN) has agreed to acquire U.S. vaccine…
AstraZeneca to acquire vaccine maker Icosavax in ~$1.1B deal
…
Icosavax enters agreement to be acquired by Astrazeneca
…
AstraZeneca to buy U.S.-based Icosavax for up to $1.1 billion
AstraZeneca to buy U.S.-based Icosavax for up to $1.1 billion…
AstraZeneca to Buy Icosavax for Up to $1.1 Bln
…
AstraZeneca to acquire Icosavax
News Release
Regulatory News Service
12 December 2023
AstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase…
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca…
Drugmaker investing $228 million, adding hundreds of new jobs in Cincinnati
The company has secured multiple new agreements since it bought AstraZenecas 580,000-square-foot West Chester facility.…
AstraZeneca (AZN) to Acquire Vaccine Maker Icosavax for $1.1B
AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Icosavax, for a total deal value of up to $1.1 billion.…
AstraZeneca Is Feeling The Weight Of The Market In 2023
…
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
Itll take a few years for its latest moves to pay off, assuming they do.…
CORRECTION: Newsletter December 2023 – Summing up the year with a Christmas message and Cline’s bright view of the future
In our Newsletter published on 7TH December 2023, a section was included related to AstraZeneca BioVentureHub. This was not officially…
ALLR: Stenoparib Clinical Update
By John Vandermosten, CFA
NASDAQ:ALLR
Early Results - Phase II Stenoparib
Allarity Therapeutics, Inc. (NASDAQ:ALLR) provided an update to investors on its…
Global Artificial Intelligence In Precision Medicine Market Size To Worth USD 5.79 Billion By 2032 | CAGR of 16.3%
The Global Artificial Intelligence In Precision Medicine Market Size was valued at USD 1.28 Billion in 2022 and the Global…
AstraZeneca and the world according to GARP
AstraZeneca PLC (LSE:AZN), the Anglo-Swedish pharmaceutical giant, stands as a quintessential example of a growth at a reasonable price (GARP)…
AstraZeneca and Novo Nordisk among the top picks of this top US bank
JP Morgan has identified its top picks in the European pharmaceuticals and biotechnology sector for 2024, spotlighting large, mid, and…
AstraZeneca and Novo Nordisk among the top picks of this top US bank
JP Morgan has identified its top picks in the European pharmaceuticals and biotechnology sector for 2024, spotlighting large, mid, and…
These 3 stocks are Cowen’s best ideas for 2024 including AstraZeneca and Datadog
…
Global Melanoma Therapeutics Market Size To Worth USD 12.35 Billion By 2032 | CAGR of 9.4%
The Global Melanoma Therapeutics Market Size was valued at USD 5.03 Billion in 2022 and the Worldwide Melanoma Therapeutics Market…
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock…
AstraZeneca in pact with Absci to develop cancer drug based on AI
…
Total Voting Rights
1 December 2023 15:00 GMT
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct…
AstraZeneca halts Phase III trials for kidney disease treatment By Investing.com
AstraZeneca halts Phase III trials for kidney disease treatment…
The Pulse With Francine Lacqua 12/01/2023
The Pulse With Francine Lacqua is all about conversations with high profile guests in the beating heart of global business,…
Discontinuation of two CRYSTALIZE evidence trials
1 December 2023
Update on CRYSTALIZE evidence trials
Discontinuation of STABILIZE-CKD and DIALIZE-Outcomes Phase III trials
AstraZeneca has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes…
AstraZeneca (AZN) to Discontinue Two Studies on Lokelma
Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III…
Non-Oncology Biologics and Biosimilars Market is Booming and Expected to Grow at a CAGR of 21.8% to 2031
Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…